Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- Eli Lilly to Differentiate Byetta from Victoza
January 3, 2011
- Novartis' Zometa PIII Data Published in Lancet
January 3, 2011
- Rivaroxaban Peak Sales Expected to Exceed 2 Bil. Euro: Bayer
January 3, 2011
- Seattle Genetics, Millennium Present Positive PII Data on SGN-35 in Hodgkin's Lymphoma
January 3, 2011
- Inavir Ranked No. 1 Both in HP, GP Markets: RepTrack Survey
January 3, 2011
- Abbott Japan Starts Business Integration with Solvay
January 3, 2011
- Millennium, Seattle Genetics Report Favorable PII Results for Brentuximab in ALCL
January 3, 2011
- Novartis to Acquire Alcon
January 3, 2011
- Defendants Appeal Court Ruling on US Abilify Patent
January 3, 2011
- Hodanren, MIN-IREN Opposed to Premium for Development of New Drugs
January 3, 2011
- Nippon Kayaku Licenses Spanidin to Nordic Pharma Group
January 3, 2011
- NanoCarrier to Obtain Patents in Asia, Oceania
January 3, 2011
- MTPC, Novartis Apply for FTY720 in Japan
January 3, 2011
- Astellas Obtains Extended License on Seroquel ER Tab in Japan
January 3, 2011
- Mochida Ties Up with Gedeon Richter for Biosimilars
January 3, 2011
- Sanko Junyaku Acquires Marketing Rights for Flu Test Kit
January 3, 2011
- MTPC, Anaphore Agree to Jointly Develop Drugs for Autoimmune Diseases
January 3, 2011
- Nippon Kayaku to Lead Antibody Biosimilar Market in Japan: Nomura Securities Report
January 3, 2011
- Eisai Applies for Marketing Authorization for Embolic Beads
January 3, 2011
- Sanofi-aventis to Tie Up with Merck Serono in Oncology
January 3, 2011
ページ
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…